Casodex blev givet som umiddelbar hormonterapi eller som adjuvans til radikal prostatektomi eller strålebehandling (hovedsagelig ekstern stråling).
At 7.4 years median follow up, 27.4% and 30.7% of all CASODEX and placebo-treated patients, respectively, had experienced objective disease progression.